US20220389029A1 - Fused pyridone compound, and preparation method therefor and use thereof - Google Patents

Fused pyridone compound, and preparation method therefor and use thereof Download PDF

Info

Publication number
US20220389029A1
US20220389029A1 US17/761,983 US202017761983A US2022389029A1 US 20220389029 A1 US20220389029 A1 US 20220389029A1 US 202017761983 A US202017761983 A US 202017761983A US 2022389029 A1 US2022389029 A1 US 2022389029A1
Authority
US
United States
Prior art keywords
compound
alkyl
membered heterocycloalkyl
cycloalkyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/761,983
Other languages
English (en)
Inventor
Shuchun GUO
Jun Fan
Yang Liu
Fang Bao
Jianbiao PENG
Haibing GUO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangxi Jemincare Group Co Ltd
Shanghai Jemincare Pharmaceuticals Co Ltd
Original Assignee
Jiangxi Jemincare Group Co Ltd
Shanghai Jemincare Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangxi Jemincare Group Co Ltd, Shanghai Jemincare Pharmaceuticals Co Ltd filed Critical Jiangxi Jemincare Group Co Ltd
Publication of US20220389029A1 publication Critical patent/US20220389029A1/en
Assigned to SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD reassignment SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GUO, Shuchun, GUO, Haibing, FAN, JUN, PENG, Jianbiao, BAO, Fang, LIU, YANG
Assigned to SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD, JIANGXI JEMINCARE GROUP CO., LTD reassignment SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Definitions

  • the present disclosure relates to a compound represented by formula (I-B), an optical isomer thereof and a pharmaceutically acceptable salt thereof, and a use of the compound as a KRAS inhibitor.
  • Cancer has been ranked first among the top ten causes of death in China for 31 years, wherein lung cancer is one of the tumors with the highest incidence, and its non-small cell lung cancer accounts for more than 80%, at the same time, the incidence of lung cancer is high and there are many kinds of mutations.
  • lung cancer is one of the tumors with the highest incidence
  • non-small cell lung cancer accounts for more than 80%
  • the incidence of lung cancer is high and there are many kinds of mutations.
  • innovative drugs for cancer treatment which has important economic and social significance.
  • RAS gene is the key gene of cancers such as lung cancer, colorectal cancer and pancreatic cancer.
  • pancreatic cancer In the United States, the three cancers with the highest mortality rate (pancreatic cancer, colorectal cancer and lung cancer) happen to be the three cancers with the most common RAS mutations, accounting for 95%, 52% and 31% of the patients of these three cancers respectively.
  • KRAS mutation accounts for the absolute majority, while NRAS mutation is more common in melanoma and acute myeloid leukemia, and HRAS mutation is more common in bladder cancer and head and neck cancer.
  • KRAS mutant tumor is the most potential targeted molecular subtype of non-small cell lung cancer (NSCLC), and its mutation rate is about 15%-25% in non-small cell lung cancer (NSCLC).
  • NSCLC non-small cell lung cancer
  • KRAS mutations mainly occur at codon 12 and codon 13. The most common codon variation accounted for about 39% of the mutant NSCLCs of KRAS, which is the KRAS-G12C mutation.
  • KRAS small molecule drugs including 10 KRAS GTPase inhibitors, 4 KRAS gene inhibitors, 2 KRAS GTPase modulators and 2 KRAS gene modulators; there is 1 such drug currently under clinical research.
  • Antroquinonol the first KRAS inhibitor developed by a Taiwanese company, has entered the Phase II clinical trial of the US FDA, and Selumetinib, an inhibitor developed by AstraZeneca targeting the MEK downstream pathway of KRAS, is also undergoing Phase II clinical trials.
  • KRAS mutation is the most important tumor driver gene. This part of mutation cases accounted for a certain proportion in pancreatic cancer, lung cancer and rectal gastric cancer. At present, there is no specific targeting drug acting on this target. Therefore, the project has important medical research value and clinical application value, and has greater medical value for nation.
  • the molecular mechanism for developing KRAS-G12C small molecule drug has been basically clarified; the molecular structure and pharmacodynamics of the drug have been verified under the existing experimental conditions, and it has the characteristics of high activity and the possibility of becoming a drug.
  • the present disclosure provides a compound represented by formula (I-B), an optical isomer thereof and a pharmaceutically acceptable salt thereof,
  • R 1 , R 2 are independently selected from H, halogen and C 1-6 alkyl, the C 1-6 alkyl is optionally substituted by 1, 2 or 3 R;
  • R 3 is selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl, C 1-6 heteroalkyl, 3-6 membered heterocycloalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl-O— and C 3-6 cycloalkyl-O—, the C 1-6 alkyl, C 1-6 heteroalkyl, 3-6 membered heterocycloalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl-O— or C 3-6 cycloalkyl-O— is optionally substituted by 1, 2 or 3 R;
  • R 4 is independently selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-10 membered heteroalkyl, benzo 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl, the C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl or 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R;
  • R 5 is selected from H, C 1-6 alkyl, C 3-6 cycloalkyl, 5-6 membered heterocycloalkyl-C 1-3 alkyl-, 3-8 membered heterocycloalkyl, phenyl, naphthyl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl, the C 1-6 alkyl, C 3-6 cycloalkyl, 5-6 membered heterocycloalkyl-C 1-3 alkyl-, 3-8 membered heterocycloalkyl, phenyl, naphthyl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl or 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R;
  • L 1 is selected from —C( ⁇ O)—, —S( ⁇ O)— and —S( ⁇ O) 2 —;
  • R 6 is selected from H, CN, C 1-6 alkyl, C 1-6 alkyl-S( ⁇ O) 2 —, 3-6 membered heterocycloalkyl, —C 1-6 alkyl-3-6 membered heterocycloalkyl and C 3-6 cycloalkyl-C( ⁇ O)—, the C 1-6 alkyl, C 1-6 alkyl-S( ⁇ O) 2 —, 3-6 membered heterocycloalkyl, —C 1-6 alkyl-3-6 membered heterocycloalkyl or C 3-6 cycloalkyl-C( ⁇ O)— is optionally substituted by 1, 2 or 3 R;
  • R 7 is independently selected from H, halogen, OH, NH 2 , CN, —C( ⁇ O)—OH, C 1-6 alkyl-O—C( ⁇ O)—, —C( ⁇ O)—NH 2 , C 1-6 alkyl, C 1-6 heteroalkyl and —C 1-6 alkyl-3-6 membered heterocycloalkyl, the C 1-6 alkyl, C 1-6 heteroalkylC 1-6 alkyl-O—C( ⁇ O)— or —C 1-6 alkyl-3-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R;
  • T 1 , T 2 are independently selected from N and —C(R 8 )—;
  • R 8 is selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl and 3-6 membered heterocycloalkyl, the C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R;
  • R 9 is selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl and C 1-6 heteroalkyl, the C 1-6 alkyl or C 1-6 heteroalkyl is optionally substituted by 1, 2 or 3 R;
  • R 10 is selected from H, halogen, CN, C 1-6 alkyl, C 1-6 alkoxy and C 1-6 alkylamino, the C 1-6 alkyl, C 1-6 alkoxy or C 1-6 alkylamino is optionally substituted by 1, 2 or 3 R;
  • R is independently selected from H, halogen, OH, NH 2 , CN,
  • R′ is selected from F, Cl, Br, I, OH, NH 2 and CH 3 ;
  • ring A is independently selected from C 6-10 aryl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl;
  • n is selected from 0, 1, 2, 3 or 4;
  • n is selected from 0, 1, 2, 3 or 4;
  • D 1 is selected from 0;
  • Y is selected from N, CH or C
  • X 1 , X 2 are independently selected from —N ⁇ , —C(R 7 ) ⁇ and —C(R 7 ) 2 —C(R 7 ) ⁇ ;
  • X 1 , X 2 are independently selected from single bond, —O—, —S—, S( ⁇ O), S( ⁇ O) 2 , —N(R 6 )—, —C( ⁇ O)—, —C(R 7 ) 2 — and —C(R 7 ) 2 —C(R 7 ) 2 —;
  • the above 3-6 membered heterocycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocycloalkyl, 5-10 membered heteroaryl or C 1-6 heterocycloalkyl comprises 1, 2, or 3 heteroatoms or heteroatomic groups independently selected from —O—, —NH—, —S—, —C( ⁇ O)—, —C( ⁇ O)O—, —S( ⁇ O)—, —S( ⁇ O) 2 and N.
  • the present disclosure also provides a compound represented by formula (I-A), an optical isomer thereof and a pharmaceutically acceptable salt thereof,
  • R 1 , R 2 are independently selected from H, halogen and C 1-6 alkyl, the C 1-6 alkyl is optionally substituted by 1, 2 or 3 R;
  • R 3 is selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl, C 1-6 heteroalkyl, 3-6 membered heterocycloalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl-O— and C 3-6 cycloalkyl-O—, the C 1-6 alkyl, C 1-6 heteroalkyl, 3-6 membered heterocycloalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl-O— or C 3-6 cycloalkyl-O— is optionally substituted by 1, 2 or 3 R;
  • R 4 is independently selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl, the C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl or 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R;
  • R 5 is selected from H, C 1-6 alkyl, C 3-6 cycloalkyl, 5-6 membered heterocycloalkyl-C 1-3 alkyl-, 3-8 membered heterocycloalkyl, phenyl, naphthyl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl, the C 1-6 alkyl, C 3-6 cycloalkyl, 5-6 membered heterocycloalkyl-C 1-3 alkyl-, 3-8 membered heterocycloalkyl, phenyl, naphthyl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl or 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R;
  • L 1 is selected from —C( ⁇ O)—, —S( ⁇ O)— and —S( ⁇ O) 2 —;
  • R 6 is selected from H, CN, C 1-6 alkyl, C 1-6 alkyl-S( ⁇ O) 2 —, 3-6 membered heterocycloalkyl, —C 1-6 alkyl-3-6 membered heterocycloalkyl and C 3-6 cycloalkyl-C( ⁇ O)—, the C 1-6 alkyl, C 1-6 alkyl-S( ⁇ O) 2 —, 3-6 membered heterocycloalkyl, —C 1-6 alkyl-3-6 membered heterocycloalkyl or C 3-6 cycloalkyl-C( ⁇ O)— is optionally substituted by 1, 2 or 3 R;
  • R 7 is independently selected from H, halogen, OH, NH 2 , CN, —C( ⁇ O)OH, C 1-6 alkyl-O—C( ⁇ O)—, —C( ⁇ O)—NH 2 , C 1-6 alkyl, C 1-6 heteroalkyl and —C 1-6 alkyl-3-6 membered heterocycloalkyl, the C 1-6 alkyl, C 1-6 heteroalkyl, C 1-6 alkyl-O—C( ⁇ O)— or —C 1-6 alkyl-3-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R;
  • T 1 , T 2 are independently selected from N and —C(R 8 )—;
  • R 8 is selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl and 3-6 membered heterocycloalkyl, the C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R;
  • R is independently selected from H, halogen, OH, NH 2 , CN,
  • R′ is selected from F, Cl, Br, I, OH, NH 2 and CH 3 ;
  • ring A is independently selected from C 6-10 aryl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl;
  • n is selected from 0, 1, 2, 3 or 4;
  • X 1 , X 2 are independently selected from —N ⁇ , —C(R 7 ) ⁇ and —C(R 7 ) 2 —C(R 7 ) ⁇ ;
  • X 1 , X 2 are independently selected from single bond, —O—, —S—, S( ⁇ O), S( ⁇ O) 2 , —N(R 6 )—, —C( ⁇ O)—, —C(R 7 ) 2 — and —C(R 7 ) 2 —C(R 7 ) 2 —;
  • the above 3-6 membered heterocycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocycloalkyl, 5-10 membered heteroaryl or C 1-6 heterocycloalkyl comprises 1, 2, or 3 heteroatoms or heteroatomic groups independently selected from —O—, —NH—, —S—, —C( ⁇ O)—, —C( ⁇ O)O—, —S( ⁇ O)—, —S( ⁇ O) 2 — and N.
  • the above compounds, optical isomers thereof and pharmaceutically acceptable salts thereof are selected from:
  • X 1 , X 2 are independently selected from single bond, —O—, —S—, S( ⁇ O), S( ⁇ O) 2 , —N(R 6 )—, —C( ⁇ O)—, —C(R 7 ) 2 — and —C(R 7 ) 2 —C(R 7 ) 2 —, R 1 , R 2 , R 3 , R 4 , R 5 , L 1 , R 6 , R 7 , T 1 , T 2 , ring A and n are as defined above.
  • the above R is independently selected from H, halogen, OH, NH 2 , CN,
  • the above R is independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me, CH 2 CH 3 ,
  • R 1 , R 2 are independently selected from H, F, Me, CF 3 ,
  • the above R 3 is selected from H, halogen, OH, NH 2 , CN, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylamino, C 1-3 alkylthio, 3-6 membered heterocycloalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl-O— and C 3-6 cycloalkyl-O—, the C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylamino, C 1-3 alkylthio, 3-6 membered heterocycloalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl-O— or C 3-6 cycloalkyl-O— is optionally substituted by 1, 2 or 3 R, and other variables are as defined in the present disclosure.
  • R 3 is selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me, CF 3 ,
  • the above R 4 is independently selected from H, halogen, OH, NH 2 , CN, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylamino, C 1-3 alkylthio, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, pyridinyl, pyrimidinyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, benzofuranyl, benzothienyl and indolyl, the C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylamino, C 1-3 alkylthio, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, pyridinyl
  • R 4 is selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me, CF 3 ,
  • the above ring A is selected from phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, benzofuranyl, benzothienyl, indolyl, indazolyl, benzoimidazolyl, 1H-benzo[d]imidazolyl, benzopyrazolyl, purinyl, quinolinyl, isoquinolinyl, isoquinolin-1(2H)-one, isoindolin-1-one, benzo[d]oxazol-2(H)-one, benzo[d]oxazol-2(3H)-one, H-benzo[d
  • R 5 is selected from H, C 1-3 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydro-2H-pyranyl, piperidinyl, piperazinyl, 5-6 membered heterocycloalkyl-C 1-3 alkyl-, phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, benzofuranyl, benzothienyl, indolyl, benzoimidazolyl, benzopyrazolyl,
  • R 5 is selected from H, Me,
  • the above R 7 is independently selected from H, halogen, OH, NH 2 , CN, C 1-3 alkyl, C 1-3 alkyl-O—C( ⁇ O)—, —C( ⁇ O)—NH 2 , C 1-3 alkoxy, C 1-3 alkylamino, C 1-3 alkylthio and —C 1-3 alkyl-3-6 membered heterocycloalkyl, the C 1-3 alkyl, C 1-3 alkyl-O—C( ⁇ O)—, —C( ⁇ O)—NH 2 , C 1-3 alkoxy, C 1-3 alkylamino, C 1-3 alkylthio or —C 1-3 alkyl-3-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R, and other variables are as defined in the present disclosure.
  • R 7 is independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me, CF 3 ,
  • the above R 6 is independently selected from H, CN, C 1-3 alkyl, C 1-3 alkyl-S( ⁇ O) 2 —, 3-6 membered heterocycloalkyl, —C 1-3 alkyl-3-6 membered heterocycloalkyl and C 3-6 cycloalkyl-C( ⁇ O)—, the C 1-3 alkyl, C 1-3 alkyl-S( ⁇ O) 2 —, 3-6 membered heterocycloalkyl, —C 1-3 alkyl 3-6 membered heterocycloalkyl or C 3-6 cycloalkyl-C( ⁇ O)— is optionally substituted by 1, 2 or 3 R, and other variables are as defined in the present disclosure.
  • R 6 is independently selected from H, CN, Me, CF 3 ,
  • X 1 , X 2 are independently selected from single bond, CH 2 , CH 2 CH 2 , C( ⁇ O), O, S, NH, N(CH 3 ), S( ⁇ O), S( ⁇ O) 2 ,
  • the above R 8 is selected from H, halogen, OH, NH 2 , CN, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylamino and C 1-3 alkylthio, the C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylamino or C 1-3 alkylthio is optionally substituted by 1, 2 or 3 R, and other variables are as defined in the present disclosure.
  • R 8 is selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me, CF 3 ,
  • the disclosure also provides compounds of the following formula, optical isomers thereof and pharmaceutically acceptable salts thereof,
  • the present disclosure also provides a pharmaceutical composition, comprising the aforementioned compounds, optical isomers and pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.
  • the present disclosure also provides a use of the aforementioned compounds, optical isomers thereof and pharmaceutically acceptable salts thereof or the aforementioned pharmaceutical composition in preparing a medicament for preventing and/or treating diseases related to KRAS-G12C.
  • the above diseases related to KRAS-G12C is selected from non-small cell lung cancer, colon cancer and pancreatic cancer.
  • pharmaceutically acceptable is used herein in terms of those compounds, materials, compositions, and/or dosage forms, which are suitable for use in contact with human and animal tissues within the scope of reliable medical judgment, with no excessive toxicity, irritation, allergic reaction or other problems or complications, and is commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salt refers to a salt of the compound of the present disclosure that is prepared by reacting the compound having a specific substituent of the present disclosure with a relatively non-toxic acid or base.
  • a base addition salt can be obtained by bringing the neutral form of the compound into contact with a sufficient amount of base in a pure solution or a suitable inert solvent.
  • the pharmaceutically acceptable base addition salt includes a salt of sodium, potassium, calcium, ammonium, organic amine or magnesium, or similar salts.
  • an acid addition salt can be obtained by bringing the neutral form of the compound into contact with a sufficient amount of acid in a pure solution or a suitable inert solvent.
  • the pharmaceutically acceptable acid addition salt include an inorganic acid salt, wherein the inorganic acid includes, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, phosphorous acid, and the like; and an organic acid salt, wherein the organic acid includes, for example, acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid
  • the pharmaceutically acceptable salt of the present disclosure can be prepared from the parent compound that contains an acidic or basic moiety by conventional chemical method.
  • such salt can be prepared by reacting the free acid or base form of the compound with a stoichiometric amount of an appropriate base or acid in water or an organic solvent or a mixture thereof.
  • a short horizontal (“-”) that is not between two letters or symbols refers to the site where the substituent is attached.
  • C 1-6 alkylcarbonyl- refers to C 1-6 alkyl which is connected to the rest of the molecule through carbonyl.
  • attachment site of a substituent is obvious to those skilled in the art, for example, a halogen substituent, “-” may be omitted.
  • the wavy line indicates the point of attachment of the group to the rest of the molecule.
  • the compounds of the present disclosure may exist in specific geometric or stereoisomer or optical isomer forms.
  • the present disclosure contemplates all such compounds, including cis and trans isomers, ( ⁇ )- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers isomers, (D)-isomers, (L)-isomers, and racemic mixture and other mixtures thereof, such as enantiomeric or diastereomeric enriched mixtures, all of which are within the scope of the present disclosure.
  • Additional asymmetric carbon atoms may be present in substituents such as alkyl. All these isomers and their mixtures are included within the scope of the present disclosure.
  • the term “enantiomer” or “optical isomer” refers to stereoisomers that are mirror images of each other.
  • cis-trans isomer or “geometric isomer” is caused by the inability to rotate freely of double bonds or single bonds of ring-forming carbon atoms.
  • diastereomer refers to stereoisomers in which the molecules have two or more chiral centers and the relationship between the molecules is not mirror images.
  • tautomer or “tautomeric form” means that at room temperature, the isomers of different functional groups are in dynamic equilibrium and can be transformed into each other quickly. If tautomers possibly exist (such as in solution), the chemical equilibrium of tautomers can be reached.
  • proton tautomer also called prototropic tautomer
  • proton migration such as keto-enol isomerization and imine-enamine isomerization.
  • Valence tautomer includes some recombination of bonding electrons for mutual transformation.
  • keto-enol tautomerization is the tautomerism between two tautomers of pentane-2,4-dione and 4-hydroxypent-3-en-2-one.
  • the compound of the present disclosure may contain an unnatural proportion of atomic isotope at one or more than one atom(s) that constitute the compound.
  • the compound can be radiolabeled with a radioactive isotope, such as tritium ( 3 H), iodine-125 ( 125 I) or C-14 ( 14 C).
  • deuterated drugs can be formed by replacing hydrogen with heavy hydrogen, the bond formed by deuterium and carbon is stronger than that of ordinary hydrogen and carbon, compared with non-deuterated drugs, deuterated drugs have the advantages of reduced toxicity and side effects, increased drug stability, enhanced efficacy, extended biological half-life of drugs, etc.
  • the racemic mixture may be used in its own form or separated into individual isomers. Through resolution, a stereochemically pure compound or a mixture enriched with one or more isomers can be obtained. Methods for separating isomers are well known (see Arlinger N. L. and Eliel E. L., “Topics in Stereochemistry”, Vol. 6, Wiley Interscience, 1971), including physical methods, such as chromatography using chiral adsorbents. Single isomers in chiral form can be prepared from chiral precursors.
  • a single isomer can be obtained by chemical separation from the mixture by forming diastereomer salts with chiral acids (such as single enantiomers of 10-camphor sulfonic acid, camphor acid, ⁇ -bromocamphor acid, tartaric acid, diacetyl tartaric acid, malic acid, pyrrolidone-5-carboxylic acid, etc.), and the salt is crystallized in stages, and then one or two of the resolved bases are separated, and this process is optionally repeated; thereby obtaining one or two isomers which do not substantially contain another isomer, i.e., the desired stereoisomer with an optical purity of, for example, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5% by weight.
  • the racemate can be covalently linked to a chiral compound (auxiliary) to obtain diastereomers.
  • substituted means one or more than one hydrogen atom(s) on a specific atom are substituted with a substituent, including deuterium and hydrogen variables, as long as the valence of the specific atom is normal and the substituted compound is stable.
  • substituent is an oxygen (i.e., ⁇ O)
  • it means two hydrogen atoms are substituted.
  • Positions on an aromatic ring cannot be substituted with an oxygen.
  • optionally substituted means an atom can be substituted with a substituent or not, unless otherwise specified, the type and number of the substituent may be arbitrary as long as being chemically achievable.
  • variable such as R
  • the definition of the variable at each occurrence is independent.
  • the group can be optionally substituted with up to two R, wherein the definition of R at each occurrence is independent.
  • a combination of the substituent and/or the variant thereof is allowed only when the combination results in a stable compound.
  • substituents can be attached to any atom.
  • pyridyl as a substituent can be connected to the substituted group by any carbon atom on the pyridine ring.
  • the direction for linking is arbitrary, for example, the linking group L contained in
  • the number of atoms on a ring is usually defined as the number of elements of the ring, e.g., a “5-7 element ring” is a “ring” having 5-7 atoms in a surrounded arrangement.
  • C 1-6 alkyl refers to a linear or branched saturated hydrocarbon group containing 1 to 6 carbon atoms.
  • the C 1-6 alkyl includes C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C 6 and C 5 alkyl and the like; it can be monovalent (such as methyl), divalent (such as methylene) or multivalent (such as methine).
  • C 1-6 alkyl examples include but are not limited to methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, s-butyl, and t-butyl), pentyl (including n-pentyl, iso-pentyl and neopentyl), hexyl, etc.
  • C 1-3 alkyl refers to a linear or branched saturated hydrocarbon group containing 1 to 3 carbon atoms.
  • the C 1-3 alkyl group includes C 1-2 and C 2-3 alkyl groups and the like; it can be monovalent (such as methyl), divalent (such as methylene) or multivalent (such as methine).
  • Examples of C 1-3 alkyl include but are not limited to methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), etc.
  • heteroalkyl refers to a stable straight-chain or branched-chain alkyl radical or a composition thereof composed of a certain number of carbon atoms and at least one heteroatom or heteroatom group.
  • the heteroatoms are selected from B, O, N, and S, wherein nitrogen and sulfur atoms are optionally oxidized, and nitrogen heteroatoms are optionally quaternized.
  • the heteroatom group is selected from —C( ⁇ O)O—, —C( ⁇ O)—, —C( ⁇ S)—, —S( ⁇ O), —S( ⁇ O) 2 —, —C( ⁇ O)N(H)—, —N(H)—, —C( ⁇ NH)—, —S( ⁇ O) 2 N(H)— and —S( ⁇ O)N(H)—.
  • the heteroalkyl is C 1-6 heteroalkyl; in other embodiments, the heteroalkyl is C 1-3 heteroalkyl.
  • heteroatoms or heteroatom groups may be located at any internal position of a heteroalkyl group, including the position where the alkyl is attached to the rest of the molecule, but the terms “alkoxy”, “alkylamino” and “alkylthio” (or thioalkoxy) are customary expressions referring to those alkyl groups that are attached to the rest of the molecule by an oxygen, amino or sulfur atom, respectively.
  • heteroalkyl examples include but are not limited to —OCH 3 , —OCH 2 CH 3 , —OCH 2 CH 2 CH 3 , —OCH 2 (CH 3 ) 2 , —CH 2 —CH 2 —O—CH 3 , —NHCH 3 , —N(CH 3 ) 2 , —NHCH 2 CH 3 , —N(CH 3 )(CH 2 CH 3 ), —CH 2 —CH 2 —NH—CH 3 , —CH 2 —CH 2 —N(CH 3 )—CH 3 , —SCH 3 , —SCH 2 CH 3 , —SCH 2 CH 2 CH 3 , —SCH 2 (CH 3 ) 2 , —CH 2 —S—CH 2 —CH 3 , —CH 2 —CH 2 , —S( ⁇ O)—CH 3 and —CH 2 —CH 2 —S( ⁇ O) 2 —CH 3 .
  • At most two heteroatoms may be continuous, for
  • C 1-6 alkoxy refers to an alkyl group containing 1 to 6 carbon atoms that are connected to the rest of the molecule through an oxygen atom.
  • the C 1-6 alkoxy includes C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C 6 , C 5 , C 4 and C 3 alkoxy, etc.
  • C 1-6 alkoxy examples include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy, s-butoxy and t-butoxy), pentoxy (including n-pentoxy, isopentyloxy and neopentyloxy), hexyloxy, etc.
  • C 1-3 alkoxy refers to an alkyl group containing 1 to 3 carbon atoms that are connected to the rest of the molecule through an oxygen atom.
  • the C 1-3 alkoxy includes C 1-2 , C 2-3 , C 3 and C 2 alkoxy, etc.
  • Examples of C 1-3 alkoxy include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), etc.
  • C 1-6 alkylamino refers to an alkyl group containing 1 to 6 carbon atoms that are connected to the rest of the molecule through an amino group.
  • the C 1-6 alkylamino includes C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C 6 , C 5 , C 4 , C 3 and C 2 alkylamino, etc.
  • C 1-6 alkylamino examples include but are not limited to —NHCH 3 , —N(CH 3 ) 2 , —NHCH 2 CH 3 , —N(CH 3 )CH 2 CH 3 , —N(CH 2 CH 3 )(CH 2 CH 3 ), —NHCH 2 CH 2 CH 3 , —NHCH 2 (CH 3 ) 2 , —NHCH 2 CH 2 CH 2 CH 3 , etc.
  • C 1-3 alkylamino refers to an alkyl group containing 1 to 3 carbon atoms that are connected to the rest of the molecule through an amino group.
  • the C 1-3 alkylamino includes C 1-2 , C 3 and C 2 alkylamino, etc.
  • Examples of C 1-3 alkylamino include, but are not limited to, —NHCH 3 , —N(CH 3 ) 2 , —NHCH 2 CH 3 , —N(CH 3 )CH 2 CH 3 , —NHCH 2 CH 2 CH 3 , —NHCH 2 (CH 3 ) 2 , etc.
  • C 1-6 alkylthio refers to an alkyl group containing 1 to 6 carbon atoms that are connected to the rest of the molecule through a sulfur atom.
  • the C 1-6 alkylthio includes C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C 6 , C 5 , C 4 , C 3 and C 2 alkylthio, etc.
  • Examples of C 1-6 alkylthio include, but are not limited to, —SCH 3 , —SCH 2 CH 3 , —SCH 2 CH 2 CH 3 , —SCH 2 (CH 3 ) 2 , etc.
  • C 1-3 alkylthio refers to an alkyl group containing 1 to 3 carbon atoms that are connected to the rest of the molecule through a sulfur atom.
  • the C 1-3 alkylthio includes C 1-3 , C 1-2 and C 3 alkylthio, etc.
  • Examples of C 1-3 alkylthio include, but are not limited to, —SCH 3 , —SCH 2 CH 3 , —SCH 2 CH 2 CH 3 , —SCH 2 (CH 3 ) 2 , etc.
  • C 3-6 cycloalkyl refers to saturated cyclic hydrocarbon groups consisting of 3 to 6 carbon atoms in monocyclic and bicyclic systems, the C 3-6 cycloalkyl including C 3-5 , C 4-5 and C 5-6 , etc.; it may be monovalent, divalent or polyvalent.
  • Examples of C 3-6 cycloalkyl include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
  • the term “3-8-membered heterocycloalkyl” by itself or in combination with other terms refers to a saturated cyclic group consisting of 3 to 8 ring atoms, respectively, wherein 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N and the remainder are carbon atoms, wherein the nitrogen atoms are optionally quaternized and the nitrogen and sulfur heteroatoms may optionally oxidized (i.e., NO and S(O) p , p is 1 or 2). It includes monocyclic, bicyclic and tricyclic ring systems, wherein the bicyclic ring system includes spiro, fused, and bridged rings.
  • the heteroatom may occupy the position where the heterocycloalkyl is attached to the rest of the molecule.
  • the 3-8-membered heterocycloalkyl includes 3-6 membered, 3-5 membered, 4-6 membered, 5-6 membered, 4 membered, 5 membered and 6 membered heterocycloalkyl, etc.
  • 3-8 membered heterocycloalkyl examples include, but are not limited to, azetidinyl, oxetidinyl, thietidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxolyl, dithianyl, isoxazolidinyl, isothi
  • 3-6-membered heterocycloalkyl by itself or in combination with other terms refers to a saturated cyclic group consisting of 3 to 6 ring atoms, respectively, wherein 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N and the remainder are carbon atoms, wherein the nitrogen atoms are optionally quaternized and the nitrogen and sulfur heteroatoms may optionally oxidized (i.e., NO and S(O) p , p is 1 or 2). It includes monocyclic and bicyclic ring systems, wherein the bicyclic ring system includes spiro and bridged rings.
  • the heteroatom may occupy the position where the heterocycloalkyl is attached to the rest of the molecule.
  • the 3-6 membered heterocycloalkyl includes 4-6 membered, 5-6 membered, 4 membered, 5 membered and 6 membered heterocycloalkyl, etc.
  • Examples of 3-6 membered heterocycloalkyl include, but are not limited to, azetidinyl, oxetidinyl, thietidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxolyl, dithianyl, isoxazolidinyl, iso
  • C 6-10 aromatic ring and “C 6-10 aryl” in the present disclosure can be used interchangeably, and the terms “C 6-10 aromatic ring” or “C 6-10 aryl” refer to a cyclic hydrocarbon group with conjugated ⁇ electron system composed of 6 to 10 carbon atoms, which can be a monocyclic, fused bicyclic or fused tricyclic system, wherein each ring is aromatic. It may be monovalent, divalent or multivalent, and C 6-10 aryl includes C 6-9 , C 9 , C 10 and C 6 aryl, etc. Examples of C 6-10 aryl include, but are not limited to, phenyl and naphthyl (including 1-naphthyl and 2-naphthyl, etc.).
  • 5-10 membered heteroaromatic ring and “5-10 membered heteroaryl” in the present disclosure may be used interchangeably, and the term “5-10 membered heteroaryl” refers to a cyclic group consisting of 5 to 10 ring atoms with conjugated ⁇ electronic system, of which 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. It may be a monocyclic, fused bicyclic or fused tricyclic system, wherein each ring is aromatic.
  • the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O) p , p is 1 or 2).
  • the 5-10 membered heteroaryl may be attached to the rest of the molecule through a heteroatom or a carbon atom.
  • the 5-10 membered heteroaryl includes 5-8 membered, 5-7 membered, 5-6 membered, 5 membered and 6 membered heteroaryl, etc.
  • Examples of the 5-10 membered heteroaryl include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5-oxazolyl, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1,2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl, etc.), thiazolyl (including 2-thiazolyl, 4-thiazo
  • the terms “5-6 membered heteroaromatic ring” and “5-6 membered heteroaryl” in the present disclosure may be used interchangeably, and the term “5-6 membered heteroaryl” refers to a monocyclic group consisting of 5 to 6 ring atoms with conjugated ⁇ electronic system, of which 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. Wherein the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O) p , p is 1 or 2).
  • the 5-6 membered heteroaryl may be attached to the rest of the molecule through a heteroatom or a carbon atom.
  • the 5-6 membered heteroaryl includes 5 membered and 6 membered heteroaryl.
  • Examples of the 5-6 membered heteroaryl include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5-oxazolyl, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1,2,4-triazolyl, etc.),
  • benzo-5-6 heterocycloalkyl refers to a double fused cyclic structure formed by combining a phenyl with a heterocyclic ring or combining a phenyl with a 5-6 membered heterocycloalkyl, where the substituent may be attached to other structures through the benzene ring or the 5-6 membered heterocycloalkyl ring.
  • benzo 5-6 membered heterocycloalkyl include but are not limited to
  • 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl refers to a double fused cyclic structure formed by combining a 5-6 membered heteroaryl with a heterocyclic ring or combining a 5-6 membered heteroaryl with a 5-6 membered heterocycloalkyl, where the substituent may be attached to other structures through the 5-6 membered heteroaryl or the 5-6 membered heterocycloalkyl ring.
  • benzo 5-6 membered heterocycloalkyl include but are not limited to
  • C n ⁇ n+m or C n ⁇ Cn+m includes any specific case of n to n+m carbons, for example, C 1-12 includes C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , and C 12 , and any range from n to n+m is also included, for example C 1-12 includes C 1-3 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C 6-9 , C 6-12 , and C 9-12 , etc.; similarly, n membered to n+m membered means that the number of atoms on the ring is from n to n+m, for example, 3-12 membered ring includes 3 membered ring, 4 membered ring, 5 membered ring, 6 membered ring, 7 membered ring, 8 membered ring, 9 membere
  • treatment refers to the administration of one or more pharmaceutical substances, in particular compounds of formula (I) and/or pharmaceutically acceptable salts thereof, to an individual suffering from a disease or having symptoms of the disease, for the purpose of curing, alleviating, mitigating, modifying, healing, improving, ameliorating or affecting the disease or symptoms of the disease.
  • prevention refers to the administration of one or more pharmaceutical substances, especially the compound of formula (I) described herein and/or pharmaceutically acceptable salts thereof, to an individual with a constitution susceptible to the disease, to prevent the individual from suffering from the disease.
  • the terms “treating”, “contacting” and “reacting” refer to adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or desired products. It should be understood that the reaction to produce the indicated and/or desired products may not necessarily come directly from the combination of the two reagents initially added, i.e. there may be one or more intermediates generated in the mixture, which eventually lead to the formation of the indicated and/or desired products.
  • the term “effective amount” refers to an amount generally sufficient to produce a beneficial effect on an individual.
  • the effective amount of a compound of the present disclosure can be determined by conventional methods (e.g., modeling, dose-escalation studies, or clinical trials) in combination with conventional influencing factors (e.g., mode of administration, pharmacokinetics of the compound, severity and duration of the disease, medical history of the individual, health status of the individual, degree of response of the individual to the drug, etc.).
  • the compounds of the present disclosure can be prepared by a variety of synthetic methods known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by their combination with other chemical synthesis methods, and equivalent alternatives known to those skilled in the art, preferred implementations include but are not limited to the embodiments of the present disclosure.
  • CDCl 3 refers to deuterated chloroform
  • CD 3 OD refers to deuterated methanol
  • DMSO-d 6 refers to deuterated dimethyl sulfoxide
  • TBS refers to tert-butyldimethylsilyl.
  • the compounds of the present disclosure are named according to the conventional naming principles in the art or by ChemDraw® software, and the commercially available compounds use the supplier catalog names.
  • FIG. 1 is a graph showing the relationship between the inoculation days of NCI-H358 cells and the change of body weight after administration of compound 29B of embodiment according to an embodiment of the present disclosure.
  • FIG. 2 is a graph showing the relationship between the inoculation days of NCI-H358 cells and the change of tumor volume after administration of compound 29B of embodiment according to an embodiment of the present disclosure.
  • Raw material 1-1 (2.00 g, 9.57 mmol) was dissolved in thionyl chloride (10 mL), and the mixture was heated to 80° C. to react for 16 hours. The system was concentrated to obtain a crude product, and the crude product was dissolved in dioxane (10 mL), then a mixed solution of dioxane (5 mL) and ethanol (5 mL) was added thereto at 0° C., after the addition was completed, the system was stirred at room temperature (20° C.) for 1 hour. The system was dissolved in ethyl acetate (20 mL), washed with saturated potassium carbonate solution, left to stratify, and the organic phase was dried over anhydrous sodium sulfate and concentrated to obtain yellow oily compound 1-2.
  • the system was cooled to room temperature, concentrated, diluted with water (100 mL), extracted with ethyl acetate (3 ⁇ 20 mL); then the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product.
  • the reaction mixture was washed with water (5 mL), extracted with dichloromethane (3 mL); the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product.
  • the crude product was purified by high performance liquid chromatography (separation conditions: chromatographic column Welch Ultimate XB-C18 10*250 mm, 5 ⁇ m, aqueous phase 0.15TFA, organic phase acetonitrile, gradient 52%-70%, time 12 min) to obtain compound 1A and compound 1B.
  • chromatographic column Waters Xselect CSH C18 3.5 ⁇ m, 100*4.6 mm; column temperature: 60° C.; mobile phase: water (0.01% trifluoroacetic acid solution)-acetonitrile (0.01% trifluoroacetic acid solution); acetonitrile: 5%-95% 7 min, 95% 8 min; flow rate: 1.2 mL/min. Retention time was 6.175 min
  • chromatographic column Waters Xselect CSH C18 3.5 ⁇ m, 100*4.6 mm; column temperature: 60° C.; mobile phase: water (0.01% trifluoroacetic acid solution)-acetonitrile (0.01% trifluoroacetic acid solution); acetonitrile: 5%-95% 7 min, 95% 8 min; flow rate: 1.2 mL/min. Retention time was 6.327 min.
  • the system was quenched by pouring to ice water (50 mL), extracted with methyl tert-butyl ether (3 ⁇ 50 mL); the organic phases were combined, washed once with saturated sodium chloride aqueous solution, and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product.
  • the system was raised to room temperature, quenched with water, extracted with ethyl acetate (10 mL); then the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product.
  • Step 6 Preparation of product 2A and product 2B
  • chromatographic column Waters Xbridge C18 3.5 ⁇ m, 100*4.6 mm; column temperature: 40° C.; mobile phase: water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile; acetonitrile: 5%-95% 7 min, 95% 8 min; flow rate: 1.2 mL/min. Retention time was 5.743 min.
  • chromatographic column Waters Xbridge C18 3.5 ⁇ m, 100*4.6 mm; column temperature: 40° C.; mobile phase: water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile; acetonitrile: 5%-95% 7 min, 95% 8 min; flow rate: 1.2 mL/min. Retention time was 5.879 min.
  • compound 3-8 (1.26 g, 2.83 mmol) was dissolved in N,N-dimethylformamide (15 mL), and sodium hydride (454 mg, 11.35 mmol, purity 60%) was added in batches, after the addition was completed, acetyl chloride (888.59 mg, 11.32 mmol, 807.81 ⁇ L) was added dropwise thereto. After the addition was completed, under nitrogen atmosphere, the system was heated to 100° C. and the reaction was carried out for 8 hours.
  • the pH of the system was adjusted to neutral with 1 N hydrochloric acid; and the mixture was extracted with ethyl acetate (10 mL ⁇ 2), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product.
  • the crude product was purified by preparative high performance liquid chromatography (Separation conditions: chromatographic column: Phenomenex Gemini-NX 80*30 mm*3 ⁇ m; mobile phase: [water (10 mM ammonium bicarbonate solution)-acetonitrile]; acetonitrile %: 41%-51% 9.5 min) to obtain compounds 3A and 3B.
  • Diastereoisomeric compound 3A was purified by SFC (separation conditions: chromatographic column: DAICEL CHIRALCEL OJ-H (250 mm*30 mm, 5 ⁇ m); mobile phase: [0.1% ammonia solution-ethanol]; ethanol %: 30%-30%; flow rate: 60 mL/min). After concentration, compound 3A-1 and compound 3A-2 were obtained.
  • Diastereoisomeric compound 3B was purified by SFC (separation conditions: chromatographic column: DAICEL CHIRALCEL OJ-H (250 mm*30 mm, 5 ⁇ m); mobile phase: [0.1% ammonia solution-ethanol]; ethanol %: 30%-30%; flow rate: 60 mL/min). After concentration, compound 3B-1 and compound 3B-2 were obtained.
  • the raw materials chloral hydrate (22 g, 133.01 mmol, 17.32 mL) and sodium sulfate (168.20 g, 1.18 mol, 120.14 mL) were dissolved in water (360 mL), the system was heated to 35° C., and the aqueous solution (120 mL) of raw material 4-1 (25 g, 131.57 mmol), hydrochloric acid (12 M, 14.80 mL) and hydroxylamine hydrochloride (29.26 g, 421.02 mmol) were added successively. After the addition was completed, the system was heated to 90° C. and treated for 16 hours.
  • reaction was quenched by adding 1 M hydrochloric acid to the system, diluted with water (80 mL), extracted with ethyl acetate (80 mL ⁇ 3), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product, the crude product was slurried with methanol to obtain compound 4-11, which was directly used in the next reaction without further purification.
  • the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product.
  • the pH of the system was adjusted to neutral with 1 N hydrochloric acid; and the mixture was extracted with ethyl acetate (10 mL ⁇ 2), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product.
  • the crude product was purified by preparative high performance liquid chromatography (separation conditions: chromatographic column: Phenomenex Gemini-NX 80*30 mm*3 ⁇ m; mobile phase: [water (10 mM ammonium bicarbonate solution)-acetonitrile]; acetonitrile %: 43%-73% 9.5 min) to obtain compounds 4A and 4B.
  • chromatographic column YMC-Pack ODS-A 150*4.6 mm, 5 ⁇ m; column temperature: 40° C.; mobile phase: water (0.0688% trifluoroacetic acid solution)-acetonitrile (0.0625% trifluoroacetic acid solution); acetonitrile: 10%-80% 10 min, 80% 5 min; flow rate: 1.5 mL/min.
  • chromatographic column YMC-Pack ODS-A 150*4.6 mm, 5 ⁇ m; column temperature: 40° C.; mobile phase: water (0.0688% trifluoroacetic acid solution)-acetonitrile (0.0625% trifluoroacetic acid solution); acetonitrile: 10%-80% 10 min, 80% 5 min; flow rate: 1.5 mL/min.
  • the system was cooled to room temperature, quenched with saturated ammonium chloride aqueous solution (1 L), extracted with ethyl acetate (3 ⁇ 500 mL); then the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product.
  • the crude product was purified by preparative high performance liquid chromatography (separation conditions: chromatographic column Welch Xtimate C18 10*250 mm, 5 m; column temperature 25° C.; mobile phase: water (10 mM/L ammonium bicarbonate aqueous solution)-acetonitrile; acetonitrile 32%-47% 16 min; flow rate 8 mL/min) to obtain compound 5A and compound 5B.
  • chromatographic column Waters Xbridge C18 3.5 ⁇ m, 100*4.6 mm; column temperature: 40° C.; mobile phase: water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile; acetonitrile: 5%-95% 7 min, 95% 8 min; flow rate: 1.2 mL/min.
  • chromatographic column Waters Xbridge C18 3.5 ⁇ m, 100*4.6 mm; column temperature: 40° C.; mobile phase: water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile; acetonitrile: 5%-95% 7 min, 95% 8 min; flow rate: 1.2 mL/min.
  • the reaction mixture was washed with water (5 mL), extracted with dichloromethane (3 mL); the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product.
  • the crude product was purified by preparative high performance liquid chromatography (separation conditions: chromatographic column Welch Xtimate C18 10*250 mm, 5 m; column temperature 25° C.; mobile phase: water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile; acetonitrile 28%-50% 19 min; flow rate 8 mL/min) to obtain compound 6A and compound 6B.
  • chromatographic column Waters Xbridge C18 3.5 ⁇ m, 100*4.6 mm; column temperature: 40° C.; mobile phase: water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile; acetonitrile: 5%-95% 7 min, 95% 8 min; flow rate: 1.2 mL/min.
  • chromatographic column Waters Xbridge C18 3.5 ⁇ m, 100*4.6 mm; column temperature: 40° C.; mobile phase: water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile; acetonitrile: 5%-95% 7 min, 95% 8 min; flow rate: 1.2 mL/min.
  • the crude product was dissolved in a mixed solvent of tetrahydrofuran (5 mL) and water (10 mL), lithium hydroxide (40 mg) was added thereto, after the addition was completed, the system was stirred at room temperature (20° C.) for 30 min.
  • Diastereoisomeric compound 7 was purified by SFC (separation conditions: chromatographic column: DAICEL CHIRALCEL OD (250 mm*30 mm, 10 ⁇ m); mobile phase: [0.1% ammonia solution-ethanol]; ethanol %: 40%-40%; flow rate: 70 mL/min). After concentration, compound 7A and compound 7B were obtained.
  • Raw material 8-1 (10 g, 52.351 mmol) was dissolved in thionyl chloride (30 mL), and the system was heated to 85° C. to react for 16 hours. The system was concentrated and the residue was dissolved in 1,4-dioxane (30 mL); the solution was slowly added to stirred methanol at 0° C., and the system was heated to 70° C. for 2 hours. The system was concentrated to obtain compound 8-2.
  • the pH of the system was adjusted to neutral with 1 N hydrochloric acid; and the mixture was extracted with ethyl acetate (10 mL ⁇ 2), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product.
  • the crude product was purified by preparative high performance liquid chromatography (separation conditions: chromatographic column: Agilent 10 Prep-C8 250 ⁇ 21.2 mm; column temperature: 25° C.; mobile phase: water (0.1% FA)-acetonitrile; acetonitrile ratio in mobile phase was 30%-50% in 16 min; flow rate 30 mL/min) to obtain compound 8.
  • chromatographic column Waters X-bridge C18, 4.6*100 mm, 3.5 ⁇ m; mobile phase: [water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile]; acetonitrile: 5%-95% 7 min; flow rate: 1.2 mL/min.
  • the pH of the system was adjusted to neutral with 1 N hydrochloric acid; and the mixture was extracted with ethyl acetate (10 mL ⁇ 2), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product.
  • the crude product was purified by preparative high performance liquid chromatography (separation conditions: chromatographic column: Agilent 10 Prep-C8 250 ⁇ 21.2 mm; mobile phase: [water (0.1% FA)-acetonitrile]; acetonitrile %: 30%-50% 9 min, flow rate 30 mL/min) to obtain compound 9.
  • chromatographic column Waters XSelect CSH C18, 4.6*100 mm, 3.5 ⁇ m; mobile phase: [water (0.01% trifluoroacetic acid)-acetonitrile (0.01% trifluoroacetic acid)]; acetonitrile: 5%-95% 7 min; flow rate: 1.2 mL/min.
  • the crude product was purified by preparative high performance liquid chromatography (separation conditions: chromatographic column: Welch Ultimate XB-C18 10 ⁇ 250 mm 5 m; mobile phase: [water (0.1% FA)-acetonitrile]; acetonitrile %: 50%-60% 10 min, 60% 20 min; flow rate 8 mL/min). After concentration, compound 10A and compound 10B were obtained.
  • chromatographic column Waters X-bridge C18, 4.6*100 mm, 3.5 ⁇ m; mobile phase: water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile; acetonitrile: 5%-95% 7 min; flow rate: 1.2 mL/min.
  • chromatographic column Waters X-bridge C18, 4.6*100 mm, 3.5 ⁇ m; mobile phase: water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile; acetonitrile: 5%-95% 7 min; flow rate: 1.2 mL/min.
  • the crude product was purified by preparative high performance liquid chromatography (separation conditions: chromatographic column: Welch Ultimate XB-C18 10 ⁇ 250 mm 5 m; mobile phase: [water (0.1% FA)-acetonitrile]; acetonitrile %: 50%-60% 10 min, 60% 20 min; flow rate 8 mL/min) to obtain compound 11A and compound 11B.
  • chromatographic column Waters X-bridge C18, 4.6*100 mm, 3.5 ⁇ m; mobile phase: [water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile]; acetonitrile: 5%-95% 7 min; flow rate: 1.2 mL/min.
  • chromatographic column Waters X-bridge C18, 4.6*100 mm, 3.5 ⁇ m; mobile phase: [water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile]; acetonitrile: 5%-95% 7 min; flow rate: 1.2 mL/min.
  • the crude product was purified by preparative high performance liquid chromatography (separation conditions: chromatographic column: Agilent 10 Prep-C8 250 ⁇ 21.2 mm; column temperature: 25° C.; mobile phase: water (0.1% FA)-acetonitrile; acetonitrile ratio in mobile phase was 40%-52% in 12 min, 52%-52% 16 min; flow rate 30 mL/min) to obtain compound 12B.
  • chromatographic column Waters X-bridge C18, 4.6*100 mm, 3.5 ⁇ m; mobile phase: [water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile]; acetonitrile: 5%-95% 7 min; flow rate: 1.2 mL/min.
  • chromatographic column Waters X-bridge C18, 4.6*100 mm, 3.5 ⁇ m; mobile phase: [water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile]; acetonitrile: 5%-95% 7 min; flow rate: 1.2 mL/min.
  • the crude product was purified by preparative high performance liquid chromatography (chromatographic column: Agilent 10 Prep-C8 250 ⁇ 21.2 mm; column temperature: 25° C.; mobile phase: water (0.1% FA)-acetonitrile; acetonitrile ratio in mobile phase was 25%-40% in 9 min, 40%-45% in 12 min; flow rate 30 mL/min) to obtain compound 13A and compound 13B.
  • chromatographic column Agilent 10 Prep-C8 250 ⁇ 21.2 mm; column temperature: 25° C.; mobile phase: water (0.1% FA)-acetonitrile; acetonitrile ratio in mobile phase was 25%-40% in 9 min, 40%-45% in 12 min; flow rate 30 mL/min
  • chromatographic column Waters X-bridge C18, 4.6*100 mm, 3.5 ⁇ m; mobile phase: [water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile]; acetonitrile: 5%-95% 7 min; flow rate: 1.2 mL/min.
  • chromatographic column Waters X-bridge C18, 4.6*100 mm, 3.5 ⁇ m; mobile phase: [water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile]; acetonitrile: 5%-95% 7 min; flow rate: 1.2 mL/min.
  • the crude product was purified by preparative high performance liquid chromatography (separation conditions: chromatographic column: Kinetex® 5 ⁇ m F5 100 ⁇ LC Column 150 ⁇ 21.2 mm; column temperature: 25° C.; mobile phase: water (0.1% FA)-acetonitrile; acetonitrile: 20%-35% in 10 min; flow rate 30 mL/min) to obtain compound 14.
  • the crude product was purified by preparative high performance liquid chromatography (separation conditions: chromatographic column: Kinetex® 5 ⁇ m F5 100 ⁇ LC Column 150 ⁇ 21.2 mm; column temperature: 25° C.; mobile phase: water (0.1% FA)-acetonitrile; acetonitrile: 15%-35% in 10 min, 35%-35% in 16 min; flow rate 30 mL/min) to obtain compound 15.
  • chromatographic column Waters Xbridge C18 3.5 ⁇ m, 100*4.6 mm; chromatographic column temperature: 40° C.; mobile phase: water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile; acetonitrile: 5%-95% 7 min, 95% 8 min; flow rate: 1.2 mL/min.
  • reaction mixture was diluted with water (10 mL), extracted with ethyl acetate (20 mL ⁇ 2); the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure; then the crude product was separated by preparative high performance liquid chromatography (separation conditions: chromatographic column: Phenomenex Gemini-NX 80*30 mm*3 m; mobile phase: [water (10 mM ammonium bicarbonate)-acetonitrile]; acetonitrile %: 36%-66%, 9.5 min) to obtain compound 16A (peak 1) and compound 16B (peak B).
  • Diastereoisomeric compound 16A was purified by SFC (separation conditions: chromatographic column: DAICEL CHIRALPAK AD-H (250 mm*30 mm, 5 ⁇ m); mobile phase: [CO 2 -isopropanol (0.1% ammonia)]; isopropanol %: 35%). After concentration, compound 16A-1 and compound 16A-2 were obtained.
  • chromatographic column Chiralpak AD-3 50 ⁇ 4.6 mm I.D., 3 ⁇ m; column temperature: 35° C.; mobile phase: CO 2 -isopropanol (0.05% DEA); isopropanol: 5%-40% 2 min, 40% 1.2 min, 5% 0.8 min; flow rate: 4 mL/min.
  • chromatographic column Chiralpak AD-3 50 ⁇ 4.6 mm I.D., 3 ⁇ m; column temperature: 35° C.; mobile phase: CO 2 -isopropanol (0.05% DEA); isopropanol: 5%-40% 2 min, 40% 1.2 min, 5% 0.8 min; flow rate: 4 mL/min.
  • Step 8 Preparation of Compounds 16B-1 and 16B-2
  • Diastereoisomeric compound 16B was purified by SFC (separation conditions: chromatographic column: DAICEL CHIRALPAK AD-H (250 mm*30 mm, 5 ⁇ m); mobile phase: [CO 2 -isopropanol (0.1% ammonia)]; isopropanol %: 35%). After concentration, compound 16B-1 and compound 16B-2 were obtained.
  • chromatographic column column: Chiralpak AD-3 50 ⁇ 4.6 mm I.D., 3 ⁇ m; column temperature: 35° C.; mobile phase: CO 2 -isopropanol (0.05% DEA); isopropanol: 5%-40% 2 min, 40% 1.2 min, 5% 0.8 min; flow rate: 4 mL/min.
  • chromatographic column column: Chiralpak AD-3 50 ⁇ 4.6 mm I.D., 3 ⁇ m; column temperature: 35° C.; mobile phase: CO 2 -isopropanol (0.05% DEA); isopropanol: 5%-40% 2 min, 40% 1.2 min, 5% 0.8 min; flow rate: 4 mL/min.
  • the crude product was purified by preparative high performance liquid chromatography (separation conditions: chromatographic column: Agilent 10 Prep-C8 250 ⁇ 21.2 mm; column temperature: 25° C.; mobile phase: water (0.1% FA FA)-acetonitrile; acetonitrile: 20%-40% in 12 min; flow rate 30 mL/min) to obtain compound 17.
  • chromatographic column Waters X-bridge C18, 4.6*100 mm, 3.5 ⁇ m; mobile phase: [water (10 mM ammonium bicarbonate aqueous solution)-acetonitrile]; acetonitrile: 5%-95% 7 min; flow rate: 1.2 mL/min.
  • compound 4-8 (8.6 g, 26.24 mmol) was dissolved in acetonitrile (40 mL), and cuprous iodide (5.05 g, 26.51 mmol) and potassium iodide (8.84 g, 53.27 mmol) and tert-butyl nitrite (5.66 g, 54.85 mmol, 6.52 mL) were added successively, then the reaction was heated to 80° C. and stirred for 2 hours.
  • compound 18-1 (6.5 g, 14.82 mmol) and 2-isopropyl-4-methyl-pyridin-3-amine (2.60 g, 17.31 mmol) were dissolved in toluene (10 mL), and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (950 mg, 1.64 mmol), tris(dibenzylideneacetone)dipalladium (1.5 g, 1.64 mmol) and cesium carbonate (14.49 g, 44.46 mmol) were added successively, and the reaction was heated to 100° C. and stirred for 16 hours.
  • compound 18-2 (3.2 g, 6.94 mmol) was dissolved in N, N-dimethylformamide (30 mL), sodium hydride (1.39 g, 34.71 mmol, 60%) was added and stirred for 20 min, then acetyl chloride (2.73 g, 34.71 mmol, 2.48 mL) was added and the reaction was raised to 25° C. and stirred for 16 hours.
  • compound 18-3 (580 mg, 1.15 mmol) was dissolved in toluene (10 mL), and potassium tert-butoxide (1.0 M tetrahydrofuran solution, 3.74 mL) was added to react at 25° C. and stirred for 30 min.
  • the reaction mixture was quenched with water (20 mL), the pH was adjusted to 7.0 by adding 1.0 M hydrochloric acid; and the mixture was extracted by ethyl acetate (30 mL ⁇ 3); the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product 18-4, which was directly used in the next reaction without further purification.
  • compound 18-4 500 mg, 1.06 mmol was dissolved in acetic acid (10 mL), then concentrated nitric acid (1.23 g, 19.51 mmol, 878.20 ⁇ L) was added, and the reaction was heated to 80° C. and stirred for 2 hours.
  • the reaction mixture was concentrated under reduced pressure to remove most of the acetic acid, cooled to 0° C., added with water (50 mL), filtered, and the filter cake was dried under vacuum to obtain crude product 18-5, which was directly used in the next reaction without further purification.
  • compound 18-7 (350 mg, 480.65 ⁇ mol) was dissolved in N-methylpyrrolidone (10 mL), and 4 ⁇ molecular sieve (500 mg) and lithium bis(trimethylsilyl)amine (1 M tetrahydrofuran solution, 1.44 mL) were added thereto successively, and the reaction was heated to 130° C. and stirred for 16 hours.
  • compound 18-8 (150 mg, 220.21 ⁇ mol) was dissolved in dichloromethane (3 mL) and boron tribromide (275.84 mg, 1.10 mmol, 106.09 ⁇ L) was added, and the reaction was stirred at 25° C. for 2 hours. The reaction mixture was quenched by adding methanol (10 mL), stirred for 10 min, and concentrated under reduced pressure to obtain the crude product 18-9, which was directly used in the next reaction without further purification.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
US17/761,983 2019-09-20 2020-09-21 Fused pyridone compound, and preparation method therefor and use thereof Pending US20220389029A1 (en)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
CN201910892032 2019-09-20
CNCN201910892032.X 2019-09-20
CNCN201911129688.2 2019-11-18
CN201911129688 2019-11-18
CNCN201911157939.8 2019-11-22
CN201911157939 2019-11-22
CNCN202010054188.3 2020-01-17
CN202010054188 2020-01-17
CNCN202010102546.3 2020-02-19
CN202010102546 2020-02-19
CN202010230303 2020-03-27
CNCN202010230303.8 2020-03-27
CN202010306926 2020-04-17
CNCN202010306926.9 2020-04-17
CNCN202010367694.8 2020-04-30
CN202010367694 2020-04-30
CN202010967317 2020-09-15
CNCN202010967317.8 2020-09-15
PCT/CN2020/116510 WO2021052499A1 (zh) 2019-09-20 2020-09-21 稠合吡啶酮类化合物及其制备方法和应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNPCT/CN20/16510 A-371-Of-International 2019-09-20 2020-09-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/101,515 Continuation US12122787B2 (en) 2019-09-20 2023-01-25 Fused pyridone compound, and preparation method therefor and use thereof

Publications (1)

Publication Number Publication Date
US20220389029A1 true US20220389029A1 (en) 2022-12-08

Family

ID=74883935

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/761,983 Pending US20220389029A1 (en) 2019-09-20 2020-09-21 Fused pyridone compound, and preparation method therefor and use thereof

Country Status (15)

Country Link
US (1) US20220389029A1 (https=)
EP (1) EP4043464A4 (https=)
JP (1) JP7642619B2 (https=)
KR (1) KR20220086573A (https=)
CN (5) CN118619971A (https=)
AU (1) AU2020350745B2 (https=)
BR (1) BR112022005193A2 (https=)
CA (1) CA3155066A1 (https=)
CL (1) CL2022000666A1 (https=)
CO (1) CO2022004686A2 (https=)
IL (1) IL291467B1 (https=)
MX (1) MX2022003401A (https=)
PH (1) PH12022550681A1 (https=)
TW (1) TWI761961B (https=)
WO (1) WO2021052499A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11697657B2 (en) 2019-10-28 2023-07-11 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS G12C mutant
US20240158417A1 (en) * 2019-10-30 2024-05-16 Genfleet Therapeutics (Shanghai) Inc. Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
US12065430B2 (en) 2018-10-26 2024-08-20 Taiho Pharmaceutical Co., Ltd. Indazole compound or salt thereof
US12152034B2 (en) 2020-11-18 2024-11-26 Relay Therapeutics, Inc. FGFR inhibitors and methods of making and using the same
US12466840B2 (en) 2023-10-20 2025-11-11 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS proteins
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
US12522605B2 (en) 2019-05-13 2026-01-13 Relay Therapeutics, Inc. FGFR inhibitors and methods of use thereof

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3849535A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
EP3849537B1 (en) 2018-09-10 2024-10-23 Mirati Therapeutics, Inc. Combination therapies
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
MX2021002804A (es) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
TW202132316A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
WO2021197499A1 (zh) * 2020-04-03 2021-10-07 南京明德新药研发有限公司 八氢吡嗪并二氮杂萘啶二酮类化生物
WO2022037630A1 (zh) * 2020-08-21 2022-02-24 浙江海正药业股份有限公司 四环类衍生物、其制备方法及其医药上的用途
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
CA3194067A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Ras inhibitors
JP2023553492A (ja) 2020-12-15 2023-12-21 ミラティ セラピューティクス， インコーポレイテッド アザキナゾリン汎ＫＲａｓ阻害剤
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2022143995A1 (zh) * 2020-12-31 2022-07-07 正大天晴药业集团股份有限公司 四环类化合物及其医药用途
CN116964056B (zh) * 2021-03-25 2026-04-10 上海济煜医药科技股份有限公司 稠合吡啶酮类化合物盐型、晶型及其应用
CN115124533A (zh) * 2021-03-26 2022-09-30 浙江海正药业股份有限公司 四环类衍生物、其制备方法和其医药上的用途
CN116848111A (zh) * 2021-03-26 2023-10-03 浙江海正药业股份有限公司 一种kras抑制剂关键中间体及其制备方法
CN116113632B (zh) * 2021-03-30 2025-08-29 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
WO2022223037A1 (zh) * 2021-04-22 2022-10-27 劲方医药科技(上海)有限公司 Kras抑制剂的盐或多晶型物
WO2023001141A1 (en) * 2021-07-23 2023-01-26 Shanghai Zion Pharma Co. Limited Kras g12d inhibitors and uses thereof
CN117222654A (zh) * 2021-09-06 2023-12-12 苏州赞荣医药科技有限公司 Kras g12c抑制剂和其用途
WO2023116895A1 (zh) * 2021-12-24 2023-06-29 劲方医药科技(上海)有限公司 Kras抑制剂的多晶型物及其制备方法和用途
CN121466307A (zh) * 2022-04-01 2026-02-06 劲方医药科技(上海)股份有限公司 药物组合物、其用途及癌症的治疗方法
US12600723B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US12600722B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer
WO2025016436A1 (zh) * 2023-07-19 2025-01-23 上海济煜医药科技有限公司 Kras抑制剂的制备方法、其中间体和其中间体的制备方法
CN121773111A (zh) * 2023-08-15 2026-03-31 劲方医药科技(上海)股份有限公司 吡嗪并萘啶二酮类化合物的制备方法及其中间体
TW202529768A (zh) 2023-09-29 2025-08-01 大陸商德昇濟醫藥（無錫）有限公司 癌症治療的療法
WO2025256521A1 (zh) * 2024-06-11 2025-12-18 上海济煜医药科技有限公司 作为kras抑制剂的稠合吡啶酮类化合物的制备方法、中间体及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020239123A1 (zh) * 2019-05-31 2020-12-03 上海翰森生物医药科技有限公司 芳香杂环类衍生物调节剂、其制备方法和应用
US12054497B2 (en) * 2019-10-30 2024-08-06 Genfleet Therapeutics (Shanghai)Inc. Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3055290B1 (en) * 2013-10-10 2019-10-02 Araxes Pharma LLC Inhibitors of kras g12c
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
ES2898765T3 (es) * 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
US10428064B2 (en) * 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
RU2722149C1 (ru) * 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
KR20180081596A (ko) * 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
US9988357B2 (en) * 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US20200010479A1 (en) * 2017-02-03 2020-01-09 The University Of North Carolina At Chapel Hill Inhibitors of microbial beta-glucuronidase enzymes and uses thereof
EP3621968A1 (en) * 2017-05-11 2020-03-18 Astrazeneca AB Heteroaryl compounds that inhibit g12c mutant ras proteins
AU2018273356B2 (en) * 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US10597405B2 (en) * 2017-12-08 2020-03-24 Astrazeneca Ab Chemical compounds
EP3842433B1 (en) * 2018-01-19 2023-11-01 Medshine Discovery Inc. Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor
CA3098574A1 (en) * 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP3919483A4 (en) * 2019-01-29 2022-02-09 Brightgene Bio-medical Technology Co., Ltd. HETEROCYCLIC BENZOPYRIDONE COMPOUND AND USE THEREOF
CN112300194B (zh) * 2019-07-30 2022-01-14 上海凌达生物医药有限公司 一类稠环吡啶酮类化合物、制备方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020239123A1 (zh) * 2019-05-31 2020-12-03 上海翰森生物医药科技有限公司 芳香杂环类衍生物调节剂、其制备方法和应用
US12054497B2 (en) * 2019-10-30 2024-08-06 Genfleet Therapeutics (Shanghai)Inc. Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12065430B2 (en) 2018-10-26 2024-08-20 Taiho Pharmaceutical Co., Ltd. Indazole compound or salt thereof
US12522605B2 (en) 2019-05-13 2026-01-13 Relay Therapeutics, Inc. FGFR inhibitors and methods of use thereof
US11697657B2 (en) 2019-10-28 2023-07-11 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS G12C mutant
US12291538B2 (en) 2019-10-28 2025-05-06 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS G12C mutant
US12297208B2 (en) 2019-10-28 2025-05-13 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS G12C mutant
US20240158417A1 (en) * 2019-10-30 2024-05-16 Genfleet Therapeutics (Shanghai) Inc. Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
US12152034B2 (en) 2020-11-18 2024-11-26 Relay Therapeutics, Inc. FGFR inhibitors and methods of making and using the same
US12466840B2 (en) 2023-10-20 2025-11-11 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS proteins

Also Published As

Publication number Publication date
BR112022005193A2 (pt) 2022-08-16
AU2020350745A1 (en) 2022-04-07
CN119462689A (zh) 2025-02-18
CA3155066A1 (en) 2021-03-25
CN118619971A (zh) 2024-09-10
WO2021052499A1 (zh) 2021-03-25
EP4043464A4 (en) 2023-10-04
MX2022003401A (es) 2022-07-13
CO2022004686A2 (es) 2022-07-08
TWI761961B (zh) 2022-04-21
CN116947885A (zh) 2023-10-27
JP2022549171A (ja) 2022-11-24
PH12022550681A1 (en) 2023-04-24
CL2022000666A1 (es) 2022-10-14
IL291467A (en) 2022-05-01
IL291467B1 (en) 2026-03-01
KR20220086573A (ko) 2022-06-23
AU2020350745B2 (en) 2026-03-26
EP4043464A1 (en) 2022-08-17
TW202126654A (zh) 2021-07-16
CN114728968B (zh) 2024-11-15
CN119591618A (zh) 2025-03-11
CN116947885B (zh) 2026-01-23
CN114728968A (zh) 2022-07-08
JP7642619B2 (ja) 2025-03-10

Similar Documents

Publication Publication Date Title
US20220389029A1 (en) Fused pyridone compound, and preparation method therefor and use thereof
US12247036B2 (en) Tricyclic compounds for the treatment of cancer
US20230118795A1 (en) Aryl or heteroaryl pyridone or pyrimidine derivative, preparation method and use thereof
US20220298174A1 (en) Tetracyclic compound, preparation method therefor and use thereof
US20250197382A1 (en) Kif18a inhibitor
US20220064141A1 (en) Benzopyridone heterocyclic compound and use thereof
US11319330B2 (en) Tricyclic furan-substituted piperidinedione compound
NZ517788A (en) Quinuclidine compounds and drugs containing the same as the active ingredient
US20230192734A1 (en) Tricyclic compounds as egfr inhibitors
WO2021245427A1 (en) N-phenylaminocarbonyl pyridino-, pyrimidino and benzo-tropanes as modulators of gpr65
US12122787B2 (en) Fused pyridone compound, and preparation method therefor and use thereof
KR20220053637A (ko) 치환된 우레아 다이하이드로오로테이트 탈수소효소 억제제
US20250059206A1 (en) Fused ring compound acting as shp2 inhibitor
AU2015360133A1 (en) Nitromidazole compound, preparation method therefor and use thereof in drug manufacturing
US11639355B2 (en) Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors
EA051763B1 (ru) Конденсированное пиридоновое соединение, способ его получения и его применение
HK40068840A (en) Fused pyridone compound, preparation method therefor and use
HK40068840B (zh) 稠合吡啶酮类化合物及其制备方法和应用
US20260035382A1 (en) Compounds as sumo activating enzyme inhibitors
HK40072763A (en) Substituted urea dihydroorotate dehydrogenase inhibitors

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

AS Assignment

Owner name: JIANGXI JEMINCARE GROUP CO., LTD, CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD;REEL/FRAME:071099/0896

Effective date: 20220315

Owner name: SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD, CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD;REEL/FRAME:071099/0896

Effective date: 20220315

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION COUNTED, NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED